Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.

Central Nervous System

1981 • 920 citations

Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

2003 • 919 citations

Immunologically Privileged Sites

1978 • 815 citations

The JAM test A simple assay for DNA fragmentation and cell death

1991 • 632 citations

Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors

1997 • 526 citations

gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand

1998 • 490 citations

Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors

1997 • 443 citations

Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma

1997 • 405 citations

Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4⁺T lymphocytes

1999 • 383 citations

Brain tumor survival: results from the National Cancer Data Base.

1998 • 341 citations

Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine

2001 • 307 citations

Intratumoral LAK cell and interleukin-2 therapy of human gliomas

1989 • 252 citations

Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.

1999 • 249 citations

Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigens

1999 • 239 citations

Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.

1996 • 209 citations

Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.

2001 • 194 citations

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

1998 • 193 citations

T cell adoptive immunotherapy of newly diagnosed gliomas.

2000 • 160 citations

Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.

1997 • 154 citations

Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

1999 • 150 citations

Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.

2002 • 121 citations

Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms

1998 • 111 citations

Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy

1991 • 108 citations

RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma.

1995 • 107 citations

Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2

1988 • 106 citations

Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma

2002 • 105 citations

In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors

1994 • 87 citations

Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors

1996 • 74 citations

Molecular and Functional Analysis of Tyrosinase-Related Protein (TRP)-2 as a Cytotoxic T Lymphocyte Target in Patients With Malignant Glioma

2003 • 72 citations

Dangerous Liaisons between a Microbe and the Prion Protein

2003 • 59 citations

Intracerebral versus Subcutaneous Immunization with Allogeneic Fibroblasts Genetically Engineered to Secrete Interleukin-2 in the Treatment of Central Nervous System Glioma and Melanoma

1997 • 55 citations

Targeted Toxin Therapy for Malignant Astrocytoma

2000 • 47 citations

Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: Evidence for in situ T‐cell activation and therapeutic efficacy

2001 • 46 citations

Prolongation of Survival of Mice with Glioma Treated with Semiallogeneic Fibroblasts Secreting Interleukin-2

1999 • 45 citations

IL-6 Secretion by a Rat T9 Glioma Clone Induces a Neutrophil-Dependent Antitumor Response with Resultant Cellular, Antiglioma Immunity

2001 • 44 citations

Immunology and Immunotherapy in Neurosurgical Disease

2003 • 42 citations

Potent Influence of Bovine Serum Proteins in Experimental Dendritic Cell‐Based Vaccination Protocols

2003 • 36 citations

Interleukin-6 transduction of a rat T9 glioma clone results in attenuated tumorigenicity and induces glioma immunity in Fischer F344 rats.

1999 • 21 citations